In Germany and the United States, the SMA patients found by NBS with two or three copies of SMN2 who were asymptomatic before the nusinersen or onasemnogene abeparvovec treatment were also symptom-free at their last follow-up (Kay et al., 2020; Vill et al., 2021). Here, SMN2 is linked to proximal spinal muscular atrophy.